Omslagsbild

Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody

Abstract We sought to characterize the population pharmacokinetic/pharmacodynamic (PK/PD) relationship of bococizumab (RN316/PF‐04950615), a humanized IgG2Δa monoclonal antibody that binds to secreted human proprotein convertase subtilisin kexin type 9 (PCSK9), using data derived from 16 phase I, II...

Full beskrivning

Sparad:

Bibliografiska uppgifter
Huvudupphovsmän:	Ellen Q. Wang (Författare, medförfattare), Nitin Kaila (Författare, medförfattare), David Plowchalk (Författare, medförfattare), Leonid Gibiansky (Författare, medförfattare), Carla Yunis (Författare, medförfattare), Kevin Sweeney (Författare, medförfattare)
Materialtyp:	Bok
Publicerad:	Wiley, 2023-12-01T00:00:00Z.
Ämnen:	article
Länkar:	Connect to this object online.
Taggar:	Lägg till en tagg Inga taggar, Lägg till första taggen!

Liknande verk

Cholesterol-lowering Action of BNA-based Antisense Oligonucleotides Targeting PCSK9 in Atherogenic Diet-induced Hypercholesterolemic Mice
av: Tsuyoshi Yamamoto, et al.
Publicerad: (2012)

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
av: Poirier S, et al.
Publicerad: (2013)

Reduction of serum cholesterol in hypercholesterolemic rats by Guar gum
av: Saeed Samarghandian, et al.
Publicerad: (2011)

Reduction of serum cholesterol in hypercholesterolemic rats by Guar gum
av: Mohammad Reza Haeri
Publicerad: (2011)

Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond
av: Maya Safarova, et al.
Publicerad: (2024)

Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)
av: Niki Katsiki, et al.
Publicerad: (2023)

Monocyte/high-density lipoprotein cholesterol, neutrophil/high-density lipoprotein cholesterol, and lymphocyte/high-density lipoprotein cholesterol ratios as new inflammatory markers in rosacea
av: Bülent Nuri Kalaycı
Publicerad: (2023)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
av: Alessia Silla, et al.
Publicerad: (2023)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
av: article Editorial
Publicerad: (2023)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
av: Chen CC, et al.
Publicerad: (2018)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
av: Laura Oggianu, et al.
Publicerad: (2023)

The cholesterol-lowering activity of Averrhoa bilimbi L. leaves ethyl acetate fraction in hypercholesterolemic model
av: Rahmad Abdillah, et al.
Publicerad: (2022)

Risk assessment of metabolic syndrome in adolescents using the triglyceride/high-density lipoprotein cholesterol ratio and the total cholesterol/high-density lipoprotein cholesterol ratio
av: Shou-Yu Chu, et al.
Publicerad: (2019)

The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials
av: Alicia Rodríguez-Gascón, et al.
Publicerad: (2021)

Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9
av: Adorni MP, et al.
Publicerad: (2017)

Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein b for cardiovascular risk assessment - What is the right choice?
av: Shrikanth N Hegde
Publicerad: (2020)

PK-PD Analysis of Marbofloxacin against Streptococcus suis in Pigs
av: Zhixin Lei, et al.
Publicerad: (2017)

Monoclonal antibodies as potent therapeutics in dentistry.
av: Pratichi Tripathi, et al.
Publicerad: (2019)

A mechanistic PK/PD model to enable dose selection of the potent anti‐tryptase antibody (MTPS9579A) in patients with moderate‐to‐severe asthma
av: Sharon M. Rymut, et al.
Publicerad: (2023)

Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against <i>Acinetobacter baumannii</i> in Patients with Hospital-Acquired Pneumonia
av: Yingjie Zhou, et al.
Publicerad: (2022)

Editorial: Pharmacokinetics, pharmacodynamics (PK/PD) of antibiotics: A reality check
av: Markus Zeitlinger, et al.
Publicerad: (2023)

Meropenem PK/PD Variability and Renal Function: "We Go Together"
av: Jacopo Angelini, et al.
Publicerad: (2023)

Re-Assessing PK/PD Issues for Oral Protein and Peptide Delivery
av: Randall J. Mrsny, et al.
Publicerad: (2021)

Effects of Pinus eldarica Medw. Nut Extract on Blood Glucose and Cholesterol Levels in Hypercholesterolemic Alloxan-induced Diabetic Rats
av: H Fallah huseini, et al.
Publicerad: (2013)

Increased Circulating Levels of PCSK9 and Pro-Atherogenic Lipoprotein Profile in Pregnant Women with Maternal Supraphysiological Hypercholesterolemia
av: Claudette Cantin, et al.
Publicerad: (2022)

Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) and kidney stone: evidence from NHANES 2007-2018
av: Tao Chen, et al.
Publicerad: (2024)

Triglycerides and high-density lipoprotein cholesterol are associated with insulinemia in adolescents
av: Ramírez-López Guadalupe, et al.
Publicerad: (2006)

High -density lipoprotein cholesterol as a predictor for diabetes mellitus
av: Hong Wu, et al.
Publicerad: (2018)

Physiologically Based Pharmacokinetic Modeling of Monoclonal Antibodies in Pediatric Populations Using PK-Sim
av: Sumit Basu, et al.
Publicerad: (2020)

Comparing Model Performance in Characterizing the PK/PD of the Anti‐Myostatin Antibody Domagrozumab
av: Abhinav Tiwari, et al.
Publicerad: (2020)

Translational PK/PD for the Development of Novel Antibiotics-A Drug Developer's Perspective
av: Caterina Bissantz, et al.
Publicerad: (2024)

Triglyceride to high-density lipoprotein cholesterol and low-density lipoprotein cholestrol to high-density lipoprotein cholesterol ratios are predictors of cardiovascular risk in Iranian adults: Evidence from a population-based cross-sectional study
av: Karimollah Hajian-Tilaki, et al.
Publicerad: (2020)

GENETICALLY PREDICTED LIPOPROTEIN(A) IS ASSOCIATED WITH CORONARY ARTERY PLAQUE SEVERITY INDEPENDENT OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL
av: Shoa L. Clarke, MD, PhD
Publicerad: (2024)

Do high-density lipoprotein cholesterol levels really reflect cardioprotection?
av: Vaishali Venkatesh Dhat, et al.
Publicerad: (2023)

SR-BI: Linking Cholesterol and Lipoprotein Metabolism with Breast and Prostate Cancer
av: Jorge L. Gutierrez-Pajares, et al.
Publicerad: (2016)

Estimation of the presence of small dense lipoprotein cholesterol in acute ischemic stroke
av: Yasuhiro Manabe, et al.
Publicerad: (2015)

A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations
av: K Gadkar, et al.
Publicerad: (2014)

PK-PD Integration Modeling and Cutoff Value of Florfenicol against Streptococcus suis in Pigs
av: Zhixin Lei, et al.
Publicerad: (2018)

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions
av: Joshuaine Grant, et al.
Publicerad: (2023)

PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria
av: Elise Oh, et al.
Publicerad: (2023)